No description available.

Receptores ativados da proliferação de peroxissomos (PPAR) são receptores nucleares que regulam o metabolismo de gordura e glicose, adipogênese e polarização de macrófagos, e são os mediadores da ação de uma grande classe de fármacos usada no tratamento de diabetes tipo 2, as tiazolidinadionas (TZD). Enquanto as TZDs reduzem a glicose do sangue e aumentam efetivamente a sensibilidade à insulina, elas podem também apresentar efeitos colaterais como aumento do risco de complicações cardiovasculares, ganho de peso, retenção de fluido e toxicidade hepática. Por causa disso, novos fármacos que possuem respostas mais favoráveis devem ser desenvolvidos, e o mecanismo de ativação do PPAR por ligantes vem sendo intensamente examinado. Para entender a relação entre a ligação de agonistas ao PPAR e a ativação transcricional, pretendíamos primeiramente obter cristais de PPAR-LBD (domínio de ligação ao ligante) humano na forma apo. Porém, surpreendentemente, a análise do sítio de ligação ao ligante revelou a presença de três pequenas moléculas, identificadas como ácidos nonanoicos e octanoicos. Este trabalho reporta a análise da estrutura cristalográfica do PPAR LBD complexado simultaneamente com três ácidos graxos de cadeia média (AGCM), provindos de bactérias (organismo de expressão), localizados no sítio de ligação ao ligante. A análise estrutural e funcional sugere que os AGCM são agonistas parciais que estabilizam a conformação do LBD do PPAR por mecanismo independente da hélice 12. / PPARs (peroxisome proliferator activated receptors) are nuclear receptors that regulate glucose and fat metabolism, adipogenesis and macrophage polarization and mediate actions of a major class of drugs that are used to treat type 2 diabetes, the thiazolidinediones. While TZDs reduce blood glucose and improve insulin sensitivity effectively, they can also exhibit deleterious side effects such as increased cardiovascular risk, weight gain, fluid retention and liver toxicity. Because it is desirable to develop new PPAR drugs with more favorable spectrums of response, mechanisms of PPAR ligand activation have come under intense scrutiny. To understand relationships between PPAR ligand binding and transcriptional activation, we sought to obtain apo human PPAR-LBD (ligand binding domain) crystals that diffract to high resolution. More surprisingly, close analysis of the ligand binding pocket revealed the presence of three small molecules, identified as nonanoic acid and octanoic acid. Here, we report the X-ray structural analysis of the PPAR LBD complexed with three bacterial (expression organism) medium chain fatty acids (MCFAs) that simultaneously occupy the buried ligand binding pocket (LBP). Structural and functional analysis suggests that MCFAs are partial agonists that stabilize PPAR LBD conformation, through a helix 12 independent mechanism.

Thesis (Ph. D.)--Ohio State University, 2005. / Title from first page of PDF file. Document formatted into pages; contains xvii, 271 p.; also includes graphics. Includes bibliographical references (p. 245-269). Available online via OhioLINK's ETD Center

A range of biochemically diverse molecules located in the plasma membrane— such as proteins, glycans, and lipids—mediate cellular recognition events, initiation of signalling pathways, and the regulation of processes important for the normal development and function of multicellular organisms. Interactions mediated by cell surface receptors can be challenging to detect in biochemical assays, because they are often highly transient, and membrane-embedded receptors are difficult to solubilise in their native conformation. The biochemical features of low-affinity extracellular protein interactions have therefore necessitated the development of bespoke methods to detect them. Here, I develop a genome-scale cell-based genetic screening approach using CRISPR-Cas9 knockout technology that reveals cellular pathways required for specific cell surface recognition events. Using a panel of high-affinity monoclonal antibodies, I first establish a method from which I identify not only the direct receptor but also other required gene products, such as co-receptors, post-translational modi cations, and transcription factors contributing to antigen expression and subsequent antibody-antigen recognition on the surface of cells. I next adapt this method to identify cellular factors required for receptor interactions for a panel of recombinant proteins corresponding to the ectodomains of cell surface proteins to the endogenous surface receptors present on a range of cell lines. In addition to finding general cellular features recognised by many ectodomains, I also identify direct interaction partners of recombinant protein probes on cell surfaces together with intracellular genes required for such associations. Using this method, I identify IGF2R as a binding partner for the R2 subunit of GABAB receptors, providing a mechanism for the internalisation and regulation of GABAB receptor signalling. The results here demonstrate that this single approach can identify the molecular nature and cell biology of surface receptors without the need to make any prior assumptions regarding their biochemical properties.

Receptores ativados da proliferação de peroxissomos (PPAR) são receptores nucleares que regulam o metabolismo de gordura e glicose, adipogênese e polarização de macrófagos, e são os mediadores da ação de uma grande classe de fármacos usada no tratamento de diabetes tipo 2, as tiazolidinadionas (TZD). Enquanto as TZDs reduzem a glicose do sangue e aumentam efetivamente a sensibilidade à insulina, elas podem também apresentar efeitos colaterais como aumento do risco de complicações cardiovasculares, ganho de peso, retenção de fluido e toxicidade hepática. Por causa disso, novos fármacos que possuem respostas mais favoráveis devem ser desenvolvidos, e o mecanismo de ativação do PPAR por ligantes vem sendo intensamente examinado. Para entender a relação entre a ligação de agonistas ao PPAR e a ativação transcricional, pretendíamos primeiramente obter cristais de PPAR-LBD (domínio de ligação ao ligante) humano na forma apo. Porém, surpreendentemente, a análise do sítio de ligação ao ligante revelou a presença de três pequenas moléculas, identificadas como ácidos nonanoicos e octanoicos. Este trabalho reporta a análise da estrutura cristalográfica do PPAR LBD complexado simultaneamente com três ácidos graxos de cadeia média (AGCM), provindos de bactérias (organismo de expressão), localizados no sítio de ligação ao ligante. A análise estrutural e funcional sugere que os AGCM são agonistas parciais que estabilizam a conformação do LBD do PPAR por mecanismo independente da hélice 12. / PPARs (peroxisome proliferator activated receptors) are nuclear receptors that regulate glucose and fat metabolism, adipogenesis and macrophage polarization and mediate actions of a major class of drugs that are used to treat type 2 diabetes, the thiazolidinediones. While TZDs reduce blood glucose and improve insulin sensitivity effectively, they can also exhibit deleterious side effects such as increased cardiovascular risk, weight gain, fluid retention and liver toxicity. Because it is desirable to develop new PPAR drugs with more favorable spectrums of response, mechanisms of PPAR ligand activation have come under intense scrutiny. To understand relationships between PPAR ligand binding and transcriptional activation, we sought to obtain apo human PPAR-LBD (ligand binding domain) crystals that diffract to high resolution. More surprisingly, close analysis of the ligand binding pocket revealed the presence of three small molecules, identified as nonanoic acid and octanoic acid. Here, we report the X-ray structural analysis of the PPAR LBD complexed with three bacterial (expression organism) medium chain fatty acids (MCFAs) that simultaneously occupy the buried ligand binding pocket (LBP). Structural and functional analysis suggests that MCFAs are partial agonists that stabilize PPAR LBD conformation, through a helix 12 independent mechanism.

No description available.

CYP17 is an ACTH/cAMP inducible gene in the human adrenal cortex encoding a cytochrome P450 enzyme with sterol 17α-hydroxylase activity and 17,20 lyase activity essential for biosynthesis of cortisol and androgens. Studies carried out during the past decade have shown that acclerated transcription of inducible eukaryotic genes involves sequential chromatin modifications by cooperative promoter-specific transcription factors and the class of proteins called transcriptional coregulators. In the present work, we aimed to first identify important chromatin modifications and chromatin modifying complexes at the CYP17 transcription start site and nearby steroidogenic factor-1 (SF-1) binding site. Then, we asked what modifications to SF-1 occur during the interaction of this nuclear receptor with the CYP17 promoter, and what their function may be. Finally, we asked how ACTH/cAMP signaling affects SF-1-containing chromatin-modifying complexes during the early phase of transcriptional induction of CYP17. Results from chromatin immunoprecipitation (ChIP) and mammalian two hybrid experiments identified complexes including one comprised of SF-1, steroid receptor coactivator-1 (SRC-1), and the histone acetyltransferase general control nonderepressed 5 (GCN5) as cAMP-inducible, but sensitive to the SF-1 antagonist sphingosine, and able to act in stimulating CYP17 transcription. Moreover, ATPases on the promoter coincided with manipulation of nucleosome histone H2 dimer content. Next, we found that SF-1 phosphorylation by glycogen synthase kinase 3beta (GSK3beta), reciprocal dephosphorylation by phosphatase(s), and acetylation by GCN5 at nearby sites at the ligand binding pocket opening were required for efficient CYP17 transcription. This leads us to propose that ligand binding to SF-1 is controlled by these post-translational modifications. Finally, we determined that the corepressors E1A C-terminal binding proteins (CtBP) 1 and 2 are protein kinase A (PKA) targets and are sensitive to PKA-dependent NADH accumulation. These effects of PKA activation by ACTH/cAMP in adrenal cortex cells enforce CYP17 transcription concomitant with dimerization of CtBP1 and CtBP2.

Les biosenseurs sont des dispositifs analytiques utilisés pour la détection de reconnaissance moléculaire. Ils consistent en un élément biologique immobilisé en contact intime avec un transducteur approprié qui convertit un signal biochimique en un signal électrique quantifiable. Leur principe est basé sur la reconnaissance d'une ou plusieurs molécules d'intérêt en solution (le ligand), par un composant biologique (le récepteur) étroitement lié au substrat transducteur. Le senseur réagit aux interactions récepteur-ligand et produit un signal mesurable, généralement proportionnel à la concentration du ligand fixé. Les biosenseurs sont déjà utilisés dans beaucoup de domaines différents, notamment dans le domaine médical (diagnostique et thérapeutique), le contrôle de l’environnement, et l’analyse et le monitoring de processus biotechnologiques. <p><p>La recherche concerne la mise au point d’un nouveau type de biosenseurs polyvalents à haute performance. Ces senseurs utilisent un élément de transduction optique dont la surface a été fonctionnalisée en vue de permettre la détection sélective d'interactions récepteur-ligand ainsi que le dosage des molécules fixées aux récepteurs. La technique utilisée pour la détection et le dosage est celle de la Spectroscopie ATR-FTIR (Spectroscopie Infra Rouge à Transformée de Fourrier en Réflexion Total Atténuée). Le système permet la détection directe, en temps réel, et sans marquage des molécules ciblées. La spectroscopie ATR-FTIR fournit une analyse des molécules sur base de leur empreinte spectrale infra rouge (IR) caractéristique, ce qui offre une mine d'informations pour identifier les ligands. Ce nouveau système de biosenseur, appelé BIA-ATR (Biospecific Interaction Analysis – Attenuated Total Reflection) est original et offre des avantages majeurs par rapport à la plus part des biosenseurs commercialement disponibles. Il fournit à l’utilisateur le spectre IR entier du ligand étudié, permettant non seulement le dosage quantitatif de ce dernier, mais aussi d’identifier sa nature intrinsèque. Un autre avantage est sa grande sensibilité ;le senseur BIA-ATR peut détecter la fixation de petites molécules et dans certains cas, aussi les réactions chimiques associées. <p><p>Le potentiel de cette nouvelle technologie de senseur est évalué dans ce travail par son application à plusieurs systèmes d’intérêt biologique et médical :la détection de protéines en milieux complexes, appliquée à la détection du Facteur VIII de coagulation du sang impliqué dans l’hémophilie de type A ;la fixation d’une petite molécule, le phosphate (phosphorylation), sur l’ATPase gastrique, un récepteur protéique de grande taille responsable de la sécrétion d’acide dans l’estomac et la détection et dosage d’un antibiotique, la vancomycine, utilisé en soins intensifs hospitaliers dans les cas d’infections bactériennes sévères à Staphylocoques dorés.<p> / Doctorat en Sciences / info:eu-repo/semantics/nonPublished

Basic helix-loop-helix (bHLH) proteins are involved in the regulation of a multitude of developmental processes including cellular differentiation, cellular proliferation and xenobiotic metabolism. Among the members of the bHLH protein family are the products of the Pan gene Pan-1, Pan-2 and ITF -1. Pan proteins have been demonstrated to be required for proper B cell development, suggesting a unique role for Pan proteins during B cell formation. In our study we tested the function of ARNT (Ah receptor nuclear translocator) at the IgH (immunoglobulin heavy chain) enhancer. We were able to determine that ARNT appears to partially down-regulate activation at the IgH enhancer by Pan-1 in transient transfection assays by cotransfection of the multimerized murine form of the IgH enhancer elements 1-1E2, !-LE3 , and 1-1ES upstream of a luciferase reporter gene, a rodent Pan-1 (human homolog E47) expression vector, and an ARNT expression vector. Furthermore, during our investigation we discovered a putative ARNT -binding ligand that increases DNA-binding activity of the ARNT homodimer. This ligand was partially characterized by UV crosslinking studies and a variety of biochemical studies using electrophoretic mobility-shift assays. Preliminary data suggests that it is hydrophilic, heat-stable, small, and non-protein.

No description available.